{
  "docId": "019de074-2763-7087-8fbd-df19b6e58266",
  "docSlug": "1ca51573de190fbfcf19415b61000ddd",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 18 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 18,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide uses a matrix-like structure to compare past performance (9M 2022) with future focus (2023).",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-2763-7087-8fbd-df19b6e58266/8",
  "deckHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266",
  "deckJsonHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266.json",
  "deckAnchorHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "*Proforma growth. 1. Ultomiris NMOSD regulatory decision anticipated in H1 2023 in US and EU. GI = gastrointestinal; CLL = chronic lymphocytic leukaemia; SGLT2i = sodium-glucose co-transporter-2 inhibitor; aHUS = atypical haemolytic uraemic syndrome; PNH = paroxysmal nocturnal haemoglobinuria; gMG = generalised myasthenia gravis; NMOSD = neuromyelitis optica spectrum disorder. Collaboration partners: Merck (Lynparza), Daiichi Sankyo (Enhertu), Sanofi (Beyfortus), Amgen (Tezspire), Avillion (PT027).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f716f14c-8427-4208-9ed1-680b7f92b15a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.95,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "table",
      "text": "Matrix comparing 9M 2022 performance and 2023 focus across three therapy areas.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d946748-978a-43dc-9116-5d6cd552bd72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Continuing momentum in commercial execution across all therapy areas, into new diseases and geographies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c87772f0-7a26-4b4f-8aa4-4f1ab2080974",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "3aa95fc4-12a6-4507-aed4-2c529320ade3",
      "evidence": "table/data: Matrix comparing 9M 2022 performance and 2023 focus across three therapy areas.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "48ed926e-7814-46ee-a629-10f94cf90551",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "KPI Overview",
      "beatSlug": null,
      "evidence": "Financials and KPIs are presented to show strong performance and momentum.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 11,
      "from": 3,
      "beatId": "577d5e60-d812-43a3-83a5-243b94cfd455",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "Executive Summary",
      "beatSlug": null,
      "evidence": "Summarizing the company's position and strategy for growth.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "88983257-4d74-4000-ae54-8166a2051abc",
      "evidence": "The loop is visible in how the presentation starts with the company's mission and weaves through its growth strategy.",
      "position": 0,
      "objective": "To explain why AstraZeneca is positioned for growth and how it plans to achieve it",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}